ACS Management In COVID-19 Patients Globally, a large number of COVID-19 patients have presented with cardiovascular disease (CVDs), thereby increasing the risk of morbidity and mortality. Moreover, acute coronary syndrome (ACS) management requires modifications based on risk stratification. Ticagrelor - Latest Advances Clopidogrel remained the gold standard along with aspirin for several years of DAPT in patients with ACS although no survival benefit has ever been shown with Clopidogrel despite increasing loading doses.
Newly developed P2Y12 inhibitor, Ticagrelor is more potent, more predictable and has a faster onset of action than Clopidogrel. Numerous ground breaking trials on Ticagrelor have been published in recent times which not only expands the indication to a larger population, but also challenges the need of DAPT. In this regard, Access 360 and Docplexus have organized an…
